Janus Kinase Inhibitors

Janus Kinase Inhibitor

Arthritis, Rheumatoid

<section class="Section" data-sectioncode="34089-3"><a name="section-9"></a><h1>11 DESCRIPTION</h1>RINVOQ and RINVOQ LQ are formulated with upadacitinib, a JAK inhibitor. Upadacitinib has the following chemical name: (3S,4R)-3-Ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide hydrate (2:1). The strength of upadacitinib is based on anhydrous upadacitinib. The solubility of upadacitinib in water is 38 to less than 0.2 mg/mL across a pH range of 2 to 9 at 37 oC. Upadacitinib has a molecular weight of 389.38 g/mol and a molecular formula of C17H19F3N6O • ½ H2O. The chemical structure of upadacitinib is: <img alt="upadacitinib-chem-structure" src="rinvoq-01.jpg"/>RINVOQ 15 mg extended-release tablets for oral administration are purple, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a15’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, ferrosoferric oxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 30 mg extended-release tablets for oral administration are red, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a30’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide. RINVOQ 45 mg extended-release tablets for oral administration are yellow to mottled yellow, biconvex oblong, with dimensions of 14 x 8 mm, and debossed with ‘a45’ on one side. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hypromellose, iron oxide yellow, iron oxide red, magnesium stearate, mannitol, microcrystalline cellulose, polyvinyl alcohol, polyethylene glycol, talc, tartaric acid and titanium dioxide.RINVOQ LQ oral solution for oral administration is a 1 mg/mL clear, colorless to light yellow solution. Each 1 mL RINVOQ LQ contains 1 mg of upadacitinib as free base (equivalent to 1.02 mg upadacitinib hemihydrate) and the following inactive ingredients: citric acid anhydrous, purified water, sodium benzoate, sodium citrate dihydrate, and sucralose. </section>

Rinvoq

upadacitinib

24 HR upadacitinib 15 MG Extended Release Oral Tablet

24 HR upadacitinib 15 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 30 MG Extended Release Oral Tablet

24 HR upadacitinib 30 MG Extended Release Oral Tablet [Rinvoq]

24 HR upadacitinib 45 MG Extended Release Oral Tablet

24 HR upadacitinib 45 MG Extended Release Oral Tablet [Rinvoq]

upadacitinib 1 MG/ML Oral Solution

upadacitinib 1 MG/ML Oral Solution [Rinvoq]

Eventus Rx

Actemra

Benlysta

Bosulif

Cosentyx

Enbrel

Entyvio

Erivedge

Fasenra

Ibrance

Inlyta

Mekinist

Rituxan

Siliq

Stelara

Sutent

Tafinlar

Tarceva

Tykerb

Votrient

Xolair

Xtandi

Rinvoq | Eventus Rx

Does Eventus Rx work closely with Rinvoq and AbbVie Inc.?

Does Eventus Rx offer services for Rinvoq patients?

What conditions does Eventus Rx support?

How does Eventus Rx help with insurance?